Nicole Tubiana

Learn More
5006 Background: Phase II studies have suggested that HDC is most effective in chemosensitive AOC pts with low tumor burden. METHODS We compared the disease free-survival (DFS), overall survival(More)
BACKGROUND Trastuzumab plus chemotherapy has become the standard of care for women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Trastuzumab-based(More)
Twenty-six patients (median age 33 years) with poor-risk malignancies were treated with high-dose combination chemotherapy associating BCNU-etoposide-cytosine arabinoside and melphalan (BEAM)(More)